DUBLIN – Viratherapeutics GmbH raised €3.6 million (US$4 million) in a first closing of a series A round to complete preclinical research and to commence clinical trials of its lead oncolytic virus program, VSV-GP. Read More
Catabasis Pharmaceuticals Inc. made a respectable debut on Nasdaq after pricing its IPO, generating $60 million from the sale of 5 million common shares at $12 apiece. Read More
SHANGHAI – Hangzhou-based Ascletis Inc. is aiming for a home turf advantage with its interferon-free regimen for chronic hepatitis C, having submitted investigational new drug applications to both the Mainland Chinese and Taiwanese Food and Drug Administrations. Read More
With "fivefold increase in half-life" and "no safety complications whatsoever," CSL Behring's long-acting fusion protein that links recombinant coagulation factor IX with recombinant albumin (rIX-FP) "is going to benefit patients in an extraordinary way," Debra Kennedy, head of coagulant and oncology therapeutics, told BioWorld Today. Read More
Cleveland Biolabs Inc., said it entered a securities purchase agreement with venture capital investor David Davidovich for the sale of approximately 6.46 million unregistered common shares at $3.87 per share for a total of $25 million. Read More
Eisai Ltd., of Woodcliff Lake, N.J., said its epilepsy drug, Fycompa (perampanel), has been granted marketing clearance by European regulators for use as a once-daily, adjunctive therapy for primary generalized tonic-clonic seizures in adults and adolescents (ages 12 and older ) with idiopathic generalized epilepsy. Read More
Basilea Pharmaceutica Ltd., of Basel, Switzerland, said it started a phase I/IIa study testing its oral formulation of BAL101553, a microtubule-destabilizing small molecule designed to act as tumor checkpoint controller as it promotes tumor cell death through activation of an important checkpoint in cell proliferation. Read More
